Weekly GLP-1 receptor agonist with a clean titration shape — what to track and how it compares to semaglutide and tirzepatide.
At a glance
Dulaglutide (brand name Trulicity) is a long-acting GLP-1 receptor agonist, approved by the FDA in 2014 and by the EMA shortly after for type 2 diabetes, and later for cardiovascular risk reduction in T2D patients. It is given as a weekly subcutaneous injection. Unlike compounded peptides, dulaglutide is a fully approved pharmaceutical with a well-characterized titration schedule, which makes tracking relatively straightforward.
Dulaglutide is a fusion of two GLP-1 analog peptides linked to a modified human IgG4 Fc fragment. The Fc extension gives it a half-life of about 5 days, suitable for weekly dosing. Like other GLP-1 RAs, it lowers blood glucose by enhancing glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite.
The approved titration is well defined:
The longer you spend at each step before escalating, the better tolerated the next step usually is. Four weeks per step is the label minimum; many people benefit from longer.
For someone whose primary goal is glycemic control and who values an easy pen, dulaglutide is reasonable. For aggressive weight loss, the data favor semaglutide or tirzepatide.
Pancreatitis is rare but a real signal — persistent severe abdominal pain warrants stopping and getting lipase checked.
Average weight loss in non-diabetic populations using dulaglutide tends to be in the 3-6% range over 6 months at standard doses, less than semaglutide's 10-15% in similar trials. Glycemic improvements are reliable and dose-dependent.
Peptide IA handles a weekly-injection compound well: one injection log per week with injection-day tag, daily symptom sliders for nausea and appetite, weekly weight/waist, and a bloodwork log tied to titration steps. Plotting weight change against dose level over time makes the dose-response visible.
Boxed warning for thyroid C-cell tumors based on rodent data — contraindicated with personal or family history of medullary thyroid carcinoma or MEN 2. Use with caution in anyone with a history of pancreatitis or severe gastroparesis. Dulaglutide is a prescription medication; this article is for tracking and education, not a use recommendation.
Peptide IA is an educational and self-tracking tool. Nothing in this post is medical advice. Doses mentioned reflect what is commonly reported in research literature — they are not recommendations. Always consult a qualified physician before starting, changing, or stopping any protocol.